Scarica l'app Stockscreener
4.16
11.83%
0.44
Dopo l'orario di chiusura:
4.18
0.02
+0.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RCEL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.72
Aprire:
$3.66
Volume 24 ore:
362.38K
Relative Volume:
1.71
Capitalizzazione di mercato:
$126.85M
Reddito:
$50.14M
Utile/perdita netta:
$-35.38M
Rapporto P/E:
-2.9714
EPS:
-1.4
Flusso di cassa netto:
$-39.46M
1 W Prestazione:
+6.67%
1M Prestazione:
+26.06%
6M Prestazione:
-27.78%
1 anno Prestazione:
-52.62%
Intervallo 1D:
$3.52
$4.43
Intervallo di 1 settimana:
$3.52
$4.43
Portata 52W:
$3.22
$11.25
Avita Medical Inc Stock (RCEL) Company Profile
Nome
Avita Medical Inc
Settore
Industria
Telefono
661-568-1317
Indirizzo
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
4.16 | 113.43M | 50.14M | -35.38M | -39.46M | -1.40 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-20 | Aggiornamento | BTIG Research | Sell → Neutral |
| 2025-08-08 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-12-24 | Iniziato | D. Boral Capital | Buy |
| 2024-04-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-02 | Iniziato | Piper Sandler | Overweight |
| 2020-08-27 | Iniziato | BofA Securities | Buy |
| 2020-04-21 | Iniziato | Oppenheimer | Outperform |
| 2020-03-03 | Iniziato | BTIG Research | Buy |
Mostra tutto
Avita Medical Inc Borsa (RCEL) Ultime notizie
Avita's Road to Profitability Is in Sight - Morningstar
Ask AVITA Medical’s interim CEO your questions in Feb. 18 investor webinar Q&A - Stock Titan
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026 - Investing.com Canada
AVITA Medical (RCEL) Reports Strong Q4 2025 Performance - GuruFocus
Avita Medical Q4 Earnings Call Highlights - MarketBeat
Avita Medical (RCEL) Reports Lower Q4 Revenue Amidst Operational Transition - GuruFocus
AVITA Medical (RCEL) Q4 2025 Earnings Transcript - The Globe and Mail
Avita Medical earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Earnings call transcript: Avita Medical Q4 2025 sees steady revenue growth - Investing.com India
AVITA Medical to Announce Q4 Earnings on February 12 - Intellectia AI
AVITA Medical, Inc. SEC 10-K Report - TradingView
AVITA Medical Q4 Earnings Summary & Key Takeaways - Benzinga
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Is AVITA Medical Inc. forming a bullish divergenceEarnings Recap Summary & Fast Entry and Exit Trade Plans - mfd.ru
Bull Run: Can AVITA Medical Inc weather a recessionMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Is AVITA Medical Inc. stock a buy before product launchesTrade Risk Report & Fast Exit and Entry Trade Guides - mfd.ru
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating - Finviz
Lake Street raises price target on AVITA Medical, Inc. (RCEL) to $3.50, maintains hold rating - MSN
Avita Medical (RCEL) to Release Quarterly Earnings on Thursday - MarketBeat
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
AVITA Medical, Inc.'s (NASDAQ:RCEL) Shift From Loss To Profit - Yahoo Finance
Avita Medical Stock: Skin Regeneration Platform Is Set Up For A Turnaround (NASDAQ:RCEL) - Seeking Alpha
Buy Signal: Can AVITA Medical Inc weather a recession2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Insider Buy: Is Ellomay Capital Ltd a speculative investmentPortfolio Risk Report & High Conviction Trade Alerts - baoquankhu1.vn
Aug Summary: What is NVAWWs P E ratio telling usMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
AVITA Medical (RCEL) Analyst Rating: Maintained 'Buy' with $10 P - GuruFocus
D. Boral Capital Reaffirms Buy Rating for Avita Medical (NASDAQ:RCEL) - MarketBeat
New Highs: Will AVITA Medical Inc benefit from rate cuts2025 Year in Review & Safe Capital Allocation Plans - baoquankhu1.vn
AVITA Medical (RCEL) Showcases Breakthrough Data at 2026 Burn Sy - GuruFocus
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies - Investing News Network
First three-part AVITA burn care path cuts painful dressing changes - stocktitan.net
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Momentum Shift: Can AVITA Medical Inc maintain sales growth2025 Key Lessons & Low Drawdown Trading Strategies - baoquankhu1.vn
Volatility Watch: Is AVITA Medical Inc stock forming a triangle patternWeekly Profit Analysis & Scalable Portfolio Growth Methods - baoquankhu1.vn
AVITA Medical, Inc.'s (NASDAQ:RCEL) Path To Profitability - simplywall.st
RCEL Analyst Rating Update: Lake Street Raises Price Target | RC - GuruFocus
AVITA Medical (ASX:AVH) Posts Revenue Growth and Advances Clinical Pipeline Ahead of Key Data in 2026 - Kalkine Media
Undervalued ASX share with pathway to positive cash flow - Morningstar Australia
AVITA Medical (RCEL): Analyst Lowers Price Target, Maintains Buy Rating | RCEL Stock News - GuruFocus
D. Boral Capital Issues Pessimistic Forecast for Avita Medical (NASDAQ:RCEL) Stock Price - MarketBeat
RCEL: 2026 guidance targets $80–$85M revenue, driven by clinical innovation and focused execution - TradingView — Track All Markets
Aug Drivers: Does AUTAP have strong EBITDA marginsJuly 2025 Outlook & Safe Entry Point Identification - baoquankhu1.vn
AVITA Medical, Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook - marketscreener.com
AVITA Medical reports Q4 revenue of $17.6 million, secures new debt - Investing.com Canada
Entry Recap: Should I hold or sell AVITA Medical Inc stock in 2025Analyst Downgrade & Daily Market Momentum Tracking - Bộ Nội Vụ
AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook - Investing News Network
Avita Medical, Inc. Announces Closing of New Credit Facility with Perceptive Advisors - marketscreener.com
Avita Medical Secures New Credit Facility and Warrants - TipRanks
Avita Medical (RCEL) Projects Strong Revenue Growth for FY26 - GuruFocus
RCEL Prepares for Growth with Strengthened Business Foundation - GuruFocus
Avita Medical Inc Azioni (RCEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avita Medical Inc Azioni (RCEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| O'Toole David D | CFO |
Aug 26 '25 |
Buy |
4.52 |
2,000 |
9,040 |
31,657 |
| McNamara Robert | Director |
Aug 19 '25 |
Buy |
5.00 |
10,000 |
50,000 |
76,771 |
| O'Toole David D | CFO |
Aug 12 '25 |
Buy |
4.81 |
2,000 |
9,620 |
29,657 |
| McNamara Robert | Director |
Mar 06 '25 |
Buy |
8.30 |
11,000 |
91,300 |
56,749 |
| McNamara Robert | Director |
Feb 20 '25 |
Buy |
10.09 |
10,000 |
100,900 |
45,749 |
| O'Toole David D | CFO |
Feb 20 '25 |
Buy |
9.90 |
1,000 |
9,900 |
25,734 |
| O'Toole David D | CFO |
Feb 19 '25 |
Buy |
10.25 |
1,000 |
10,250 |
24,734 |
1.33%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):